Article,
MYC protein is a high-risk factor in mantle cell lymphoma and identifies cases beyond morphology, proliferation and TP53/p53 – a Nordic Lymphoma Group study
Contributors
Hollander, Peter
0000-0002-0226-5681
[2]
Grønbæk, Kirsten
0000-0002-1535-9601
[5]
[6]
Eskelund, Christian Winther
0000-0002-6409-8081
[5]
[6]
Räty, Riikka Katariina
0000-0001-8603-9202
[7]
Sundström, Christer
0000-0002-8160-5647
[2]
Glimelius, Ingrid Cecilia
0000-0001-6158-3041
[2]
Porwit, Anna Porwit
0000-0003-0709-2713
[1]
Jerkeman, Mats Ingvar
0000-0003-4509-6707
[1]
Ek, Sara
0000-0002-1388-4912
(Corresponding author)
[1]
Affiliations
- [1] Lund University [NORA names: Sweden; Europe, EU; Nordic; OECD];
- [2] Uppsala University [NORA names: Sweden; Europe, EU; Nordic; OECD];
- [3] Uppsala University Hospital [NORA names: Sweden; Europe, EU; Nordic; OECD];
- [4] Aiforia Technologies Plc, Helsinki, Finland [NORA names: Finland; Europe, EU; Nordic; OECD];
- [5] Rigshospitalet [NORA names: Capital Region of Denmark; Hospital; Denmark; Europe, EU; Nordic; OECD];
(... more)
Abstract
The transcription factor MYC is a well-described oncogene with an important role in lymphomagenesis, but its significance for clinical outcome in mantle cell lymphoma (MCL) remains to be determined. We performed an investigation of the expression of MYC protein in a cohort of 251 MCL patients complemented by analyses of structural aberrations and mRNA, in a sub-cohort of patients. Fourteen percent (n=35) of patients showed high MYC protein expression with >20% positive cells (MYChigh), among whom only one translocation was identified, and 86% (n=216) of patients showed low MYC protein expression. Low copy number gains of MYC were detected in ten patients, but with no correlation to MYC protein levels. However, MYC mRNA levels correlated significantly to MYC protein levels with a R2 value of 0.76. Patients with a MYChigh tumor had both an independent inferior overall survival and an inferior progression-free survival (hazard ratio [HR]=2.03, 95% confidence interval [95% CI]: 1.2-3.4 and HR=2.2, 95% CI: 1.04-4.6, respectively) when adjusted for additional high-risk features. Patients with MYChigh tumors also tended to have additional high-risk features and to be older at diagnosis. A subgroup of 13 patients had concomitant MYChigh expression and TP53/p53 alterations and a substantially increased risk of progression (HR=16.9, 95% CI: 7.4-38.3) and death (HR=7.8, 95% CI: 4.4-14.1) with an average overall survival of only 0.9 years. In summary, we found that at diagnosis a subset of MCL patients (14%) overexpressed MYC protein, and had a poor prognosis but that MYC rearrangements were rare. Tumors with concurrent MYC overexpression and TP53/p53 alterations pinpointed MCL patients with a dismal prognosis with a median overall survival of less than 3 years. We propose that MYC needs to be assessed beyond the current high-risk factors in MCL in order to identify cases in need of alternative treatment.
